OS Therapies (OSTX) Interest Expenses (2023 - 2026)

OS Therapies' (OSTX) quarterly Interest Expenses came in at $153594.0 in Q1 2026, down 89.57% on a QoQ basis from $1.5 million in Q4 2025.

OS Therapies (OSTX) Interest Expenses (2023 - 2026) Analysis & Trends

OS Therapies (OSTX) has 4 years of Interest Expenses data on file, last reported at $153594.0 in Q1 2026.

Quarterly Interest Expenses changed N/A year-over-year to $153594.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.6 million (up 33.61% YoY) and the FY2025 annual result came in at $1.5 million, down 82.67% from the prior year.
Interest Expenses retreated to $153594.0 in Q1 2026, from $1.5 million in the prior quarter.
In the past five years, Interest Expenses ranged from a high of $1.5 million in Q4 2025 to a low of $7556.0 in Q4 2024.
A 4-year average of $694256.2 and a median of $637326.5 in 2024 frame the typical range for Interest Expenses.
Annual changes were most pronounced in 2024 — Interest Expenses plunged 97.54% — and 2025, when it surged 19394.38%.
Tracing OSTX's Interest Expenses over 4 years: stood at $307534.0 in 2023, then sank by 97.54% to $7556.0 in 2024, then surged by 19394.38% to $1.5 million in 2025, then sank by 89.57% to $153594.0 in 2026.
The last three Interest Expenses figures came in at $153594.0 (Q1 2026), $1.5 million (Q4 2025), and $496972.0 (Q3 2025), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Interest Expense (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	11.00 Mn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	-
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	-
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	39.74 Mn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	82.05 Mn
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	20.27 Mn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	93.62 Mn
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	-4.89 Mn
10	OS Therapies	19.31 Mn	19.31 Mn	-	51,239.00

Download Data